Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer.

ABSTRACT:

Purpose

Cabazitaxel has been demonstrated to improve the overall survival for men with metastatic castrate-resistant prostate cancer. The purpose of this study was to determine the maximum tolerated dose for concurrent cabazitaxel with androgen deprivation and intensity modulated radiation therapy in men with high-risk prostate cancer.

Methods and materials

Twenty men were enrolled in this institutuional review board-approved phase I clinical trial using a 3 + 3 design. Patients were followed prospectively for safety, efficacy, and health-related quality of life (Expanded Prostate Index Composite). Efficacy was assessed biochemically using the Phoenix definition.

Results

With a median follow-up time of 56 months, the maximum tolerated dose of concurrent cabazitaxel wa

SUBMITTER: Lin J 

PROVIDER: S-EPMC8186272 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature